Complete GBIO Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
GBIO DCF Analysis
GBIO (Generation Bio Co.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5.9M | $19.9M | $24.9M | $31.1M | $38.9M | $48.6M | $60.7M |
| Revenue Growth % | - | Infinity% | 236.9% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $-141.2M | $-138.6M | $-142.4M | $1.2M | $1.6M | $1.9M | $2.4M | $3.0M |
| EBIT Margin % | 0.0% | -2346.9% | -715.8% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-105.9M | $-103.9M | $-106.8M | $932.4K | $1.2M | $1.5M | $1.8M | $2.3M |
| NOPAT Margin % | -Infinity% | -1760.2% | -536.9% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $8.8M | $7.4M | $2.4M | $3.0M | $3.6M | $4.2M | $5.0M | $6.0M |
| Capex / Revenue % | Infinity% | 125.3% | 12.1% | 12.1% | 11.5% | 10.9% | 10.3% | 9.8% |
| Depreciation | $5.1M | $5.3M | $4.9M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| D&A / Revenue % | Infinity% | 89.1% | 24.8% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Change in NWC | $-92.5M | $-35.2M | $-74.9M | $248.7K | $310.8K | $388.5K | $485.6K | $607.1K |
| NWC Change / Revenue % | -Infinity% | -595.6% | -376.3% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Unlevered FCF | $-17.0M | $-70.9M | $-29.4M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| UFCF % Chg. | - | -315.9% | 58.5% | Infinity% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | -Infinity% | -1200.8% | -147.8% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Discount Factor | - | - | - | 0.931 | 0.867 | 0.807 | 0.751 | 0.700 |
| Present Value of FCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| Sum of PV of UFCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.9% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.2% |
| Risk Free Rate | 4.40% |
| Market Risk Premium | 4.3% |
| Beta | 2.66 |
| Cost of Equity | 15.9% |
| Total Debt | $93.6M |
| Market Cap | $24.5M |
| Total Capital | $118.1M |
| Debt Weighting | 79.2% |
| Equity Weighting | 20.8% |
| WACC | 7.4% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $InfinityB |
| Terminal Value | $InfinityB |
| PV of Terminal Value | $InfinityB |
| Cumulative PV of UFCF | $InfinityB |
| Net Debt | $17.3M |
| Equity Value | $InfinityB |
| Shares Outstanding | 66.6M |
| Implied Share Price | $InfinityB |
| Current Share Price | $0 |
| Implied Upside/(Downside) | +Infinity% |
Valuation Summary
$Infinity
Implied Price
$0.37
Current Price
+Infinity%
Upside/Downside
7.4%
WACC
GBIO Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 7 peer companies in Healthcare
P/E Ratio
$0.00
-100.0%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$6.99
+1813.1%
Peer Median: 19.1x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for GBIO's business model and current situation.
Multiple Comparison
| Multiple | GBIO Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.3x | 0.0x | 0.0x | -Infinity% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 1.0x | 19.1x | 10.0x | -94.8% | Undervalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.00B | 0.0x | 0.0x | 334.4x | |
| $0.03B | 0.0x | 0.0x | 19.1x | |
| $0.02B | 0.0x | 0.0x | 0.0x | |
| $0.02B | 0.0x | 0.0x | 1.0x | |
| $0.03B | 0.0x | 0.0x | 0.0x | |
| $0.04B | 0.0x | 0.0x | 111.1x | |
| $0.03B | 0.0x | 0.0x | 50.1x |